Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorYaman, Sebnem
dc.contributor.authorGumusay, Ozge
dc.contributor.authorUnal, Olcun
dc.contributor.authorUlas, Arife
dc.contributor.authorElkiran, Emir T.
dc.date.accessioned2024-04-24T17:28:16Z
dc.date.available2024-04-24T17:28:16Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer. Materials and Methods: For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days). Results: Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8-20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%). Conclusions: Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients.en_US
dc.identifier.doi10.7314/APJCP.2012.13.8.3973
dc.identifier.endpage3976en_US
dc.identifier.issn1513-7368
dc.identifier.issue8en_US
dc.identifier.pmid23098502
dc.identifier.scopus2-s2.0-84873628921
dc.identifier.scopusqualityQ3
dc.identifier.startpage3973en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.8.3973
dc.identifier.urihttps://hdl.handle.net/11468/20384
dc.identifier.volume13en_US
dc.identifier.wosWOS:000311459400073
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOvarian Canceren_US
dc.subjectOral Etoposideen_US
dc.subjectToxicityen_US
dc.subjectPfsen_US
dc.titleOral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncologyen_US
dc.titleOral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu